
Srdan Verstovsek, MD, PhD, discusses the importance of the findings of the MOMENTUM trial, which assessed the use of momelotinib in managing anemia for patients with myelofibrosis.

Srdan Verstovsek, MD, PhD, discusses the importance of the findings of the MOMENTUM trial, which assessed the use of momelotinib in managing anemia for patients with myelofibrosis.

Dr Srdan Verstovsek discusses how ruxolitinib might fit into the myelofibrosis treatment landscape in the future, and highlights remaining unmet needs.

Srdan Verstovsek, MD, reviews data presented at ASH 2022 on combination ruxolitinib and selinexor for the frontline treatment of myelofibrosis.

Dr Srdan Verstovsek, MD, details how the JAK-STAT pathway is utilized in the treatment of myelofibrosis.

Srdan Verstovsek, MD, provides an overview of myelofibrosis and the clinical signs and symptoms to look for.

Dr Joshua Richter explains which patients with multiple myeloma are most suitable for triplet combination therapies.

Joshua Richter, MD, highlights key data from an update to a study investigating a selinexor triplet combination therapy.

Dr Joshua Richter explains triple class refractory myeloma and the need for more data on treatment options.

Joshua Richter, MD, reviews data from two clinical trials investigating selinexor combination therapies for the treatment of multiple myeloma.

Dr Joshua Richter describes the mechanism of action of XPO1 inhibitor selinexor and its use in treating multiple myeloma.

Joshua Richter, MD, gives an overview of relapse/refractory multiple myeloma and the available treatment options.

Srdan Verstovsek, MD, PhD, discusses the issues faced by patients with cytopenic myelofibrosis.

Srdan Verstovsek, MD, PhD, discusses the increased thrombotic risk and management for patients with essential thrombocythemia.

Srdan Verstovsek, MD, PhD, highlights what future research in myeloproliferative neoplasms looks to examine.

Srdan Verstovsek, MD, PhD, highlighted recent advancements in developing novel therapeutic strategies for myelofibrosis during SOHO 2022.

Srdan Verstovsek, MD, PhD, discusses some of the best practices to try and prevent thrombosis in patients with polycythemia vera.

In the interview with Targeted Oncology, Srdan Verstovsek, MD, PhD, discussed the FDA approval of pemigatinib for relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement. He also discussed the FIGHT-203 trial, and possibilities for pemigatinib in the future.

Srdan Verstovsek, MD, PhD, wraps up by discussing remaining unmet needs and hopes for future treatment options for patients with MF.

A commentary on considerations for long-term follow-up and management of myelofibrosis.

Srdan Verstovsek, MD, PhD, discusses the risk of transformation to acute myeloid leukemia (AML) and the potential use of bone marrow transplant in patients with MF.

A discussion of the benefits of clinical trial enrollment for MF.

Srdan Verstovsek, MD, PhD, reviews how treatment with JAK inhibitors improves symptoms, quality of life, and patient outcomes in primary MF.

Srdan Verstovsek, MD, PhD, comments on safety data from the ruxolitinib clinical trials in patients with MF.

A comprehensive review of key efficacy data from clinical trials on ruxolitinib, including COMFORT-I and COMFORT-II.

Srdan Verstovsek, MD, PhD, expands upon frontline treatment options for primary MF, including Janus kinase (JAK) inhibitors.

A focused discussion on the clinical factors that impact patient prognosis, risk assessment, and disease progression.

Srdan Verstovsek, MD, PhD, reviews the use of symptom scoring systems and prognostic models for MF risk stratification and treatment selection.

An overview of clinical criteria and tools that clinicians use for diagnosis of MF.

Srdan Verstovsek, MD, PhD, comments on the patient profile and discusses the typical presentation of patients with myelofibrosis (MF).

Srdan Verstovsek, MD, PhD, discusses the tolerability of pacritinib for patients with myelofibrosis.

Published: August 30th 2022 | Updated:

Published: January 30th 2023 | Updated:

Published: September 18th 2015 | Updated:

Published: December 8th 2015 | Updated:

Published: October 31st 2018 | Updated:

Published: March 20th 2019 | Updated: